细胞毒剂与单克隆抗体的偶联-猫眼课题宝

细胞毒剂与单克隆抗体的偶联

批准号：

3613230

负责人：

GARY S DAVID

金额：

$3.02万

依托单位：

HYBRITECH, INC.

依托单位国家：

美国

项目类别：

财政年份：

1985

资助国家：

美国

项目状态：

已结题

起止时间：

1985-09-30 至 1989-03-29

来源：

https://reporter.nih.gov/project-details/3613230

关键词：

antineoplastics combination cancer therapy cytotoxicity drug metabolism immunoconjugates immunological substance monoclonal antibody neoplasm /cancer immunotherapy neoplasm /cancer pharmacology neoplasm /cancer radionuclide therapy

项目摘要

项目成果

GARY S DAVID的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

We shall provide to NCI investigators 111In-antibody radiolabeling kits for imaging purposes. This will permit the investigators to familiarize themselves with the antibodies and to determine the feasibility of using these antibodies in therapeutic systems. We shall provide 90Y labeled monoclonal antibodies for therapeutic programs. We shall develop systems for antibody-based delivery of drugs to tumor targets. We shall demonstrate the in vitro eficacy of the drug-hapten conjugates (i.e., we shall determine retention of drug activity). We shall develop an in vivo delivery system, based on the pharmacokinetics of indium-labeled drug conugate without and with various concentrations of drug reactive antibody. We shall demonstrate tumoricidal efficacy of the delivery system. We shall prepare and submit to NCI personnel pharmaceutical grade reagents for clinical investigations.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文